Market Scenario
Market Research Future (MRFR) speculates that the U.S. uterine fibroid market is likely to garner USD 39,993.2 million, grabbing a CAGR of 3.24% during the forecast period (2016-2022). The surging prevalence of uterine fibroid in the African-American race is considered a propelling factor to the growth of the market. Uterine fibroids can be referred to as the abnormal growth which generally develops inside or on the wall of the uterus of a woman. Also termed as myomas or leiomyoma, uterine fibroids are non-cancerous growth which causes symptoms like pain in the pelvis and lower back, heavy bleeding during or between the menstrual cycle, and increased menstrual cramps along with the enlargement of the abdomen.
Request Sample Copy:
https://www.marketresearchfuture.com/sample_request/2394
Symptoms of this disease are so benign that these fibroids often go unnoticed, however, this can be detected while undergoing pelvic exam or prenatal ultrasound. The US market for uterine fibroid is expected to gain substantial boost due to the growing awareness and high investment capacity, along with superior medical facilities. The hike in investment for the healthcare sector and better investment for research & development can inspire the global uterine fibroids market further.
Segmentation:
The U.S. Uterine Fibroid Market can be segmented by type, diagnosis, and treatment. Such a segmentation relies heavily on factorial analyses that bring out insights, which can be used in the future for a better market understanding.
By type, the Uterine Fibroid Market can be studied as Submucosal Fibroids, Intramural Fibroids, Subserosal Fibroids, and others. These three segments are witnessing a substantial growth due to various reasons owing to which the market is expanding accordingly.
By diagnosis, the U.S. Uterine Fibroid market can be segmented into Computed tomography (CT), Medical Resonance Imaging (MRI) scanners, Ultrasounds, and others. Better technological integration is expected to provide high traction to the global market.
Regional Insights
The U.S. uterine fibroid market is expanding at a steady pace with a CAGR of 3.24% by the end of 2022. Economies like Texas, California, New York, and Florida are estimated to witness the highest prevalence of uterine fibroids. North America has been recorded to witness the largest market share due to the increased awareqness among the population of the region, easy accessibility to advanced technologies, and an established healthcare sector. The presence of a high number of clinics and ambulatory surgical centers and hospitals in this region has further contributed to the market’s growth. A huge number of people are undergoing hormonal disorders which are further encouraging the market growth. Moreover, the increased incidences of uterine cancer is another propelling factor.
Competitive Dashboard
The prominent players operating the U.S. uterine fibroids market comprises Cook Medical Inc. (US), AstraZeneca (England), GE Healthcare (U.K.), Boston Scientific Corporation (US), Hologic (U.S.), AbbVie Inc. (U.S.), and others.
Browse Full Report@
https://www.marketresearchfuture.com/reports/uterine-fibroid-market-2394
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
Market ScenarioMarket Research Future (MRFR) speculates that the U.S. uterine fibroid market is likely to garner USD 39,993.2 million, grabbing a CAGR of 3.24% during the forecast period (2016-2022).
Also termed as myomas or leiomyoma, uterine fibroids are non-cancerous growth which causes symptoms like pain in the pelvis and lower back, heavy bleeding during or between the menstrual cycle, and increased menstrual cramps along with the enlargement of the abdomen.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/2394Symptoms of this disease are so benign that these fibroids often go unnoticed, however, this can be detected while undergoing pelvic exam or prenatal ultrasound.
The US market for uterine fibroid is expected to gain substantial boost due to the growing awareness and high investment capacity, along with superior medical facilities.
The hike in investment for the healthcare sector and better investment for research & development can inspire the global uterine fibroids market further.Segmentation:The U.S.
Such a segmentation relies heavily on factorial analyses that bring out insights, which can be used in the future for a better market understanding.By type, the Uterine Fibroid Market can be studied as Submucosal Fibroids, Intramural Fibroids, Subserosal Fibroids, and others.
Better technological integration is expected to provide high traction to the global market.Based on the treatment, the U.S.
Uterine Fibroid Market Information By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and others), By Diagnosis (Medical Resonance Imaging (MRI) scanners, Computed Tomography (CT), Ultrasounds and others) and Treatment (Uterine Fibroid Embolization, Magnetic Resonance Guided Focused Ultrasound, Myolysis, Endometrial Ablation, Hysterectomy and Myomectomy) - Forecast to 2027Market ScenarioMarket Research Future (MRFR) speculates that the U.S. uterine fibroid market is likely to garner USD 39,993.2 million, grabbing a CAGR of 3.24% during the forecast period (2016-2022).
Also termed as myomas or leiomyoma, uterine fibroids are non-cancerous growth which causes symptoms like pain in the pelvis and lower back, heavy bleeding during or between the menstrual cycle, and increased menstrual cramps along with the enlargement of the abdomen.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/2394 Market Potential and PitfallsUterine fibroids are spreading over the entire U.S. at a rapid pace mainly due to the increased prevalence of uterine fibroids in the African-American race.
The U.S. uterine fibroid market is anticipated to touch high growth figures in the long run mainly due to the surging prevalence of uterine fibroids and the rising number of hysterectomy surgeries every year.
Several treatment options available such as pharmacotherapy, self-help techniques, invasive surgical procedures, and uterine artery embolization are propelling the market growth in the U.S.The introduction of minimally invasive surgeries such as myomectomy and hysterectomy for treating the excruciating pain of uterine fibroids is expected to encourage the market growth.
Such surgeries have reduced the chances of infection, reduced the hospital stay, and, lowered the recovery time, thereby contributing to the growth.
This has resulted in limited treatment options for uterine fibroids.
